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Figure 1. Network diagram for prevention of PPH ≥ 500 mL by mode of birth (vaginal birth). 
The nodes represent an intervention and their size is proportional to the number of trials 
comparing this intervention to any other in the network. The lines connecting each pair of 
interventions represent a direct comparison and are drawn proportional to the number of 







Figure 2. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL by mode 




Figure 3. Cumulative rankograms comparing each of the uterotonic drugs for prevention of 
PPH ≥ 500 mL by mode of birth (vaginal birth). Ranking indicates the cumulative probability 
of being the best drug, the second best, the third best, etc. The x axis shows the relative 
ranking and the y-axis the cumulative probability of each ranking. We estimate the SUrface 
underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its 







Figure 4. Network diagram for prevention of PPH ≥ 1000 mL by mode of birth (vaginal birth). 
The nodes represent an intervention and their size is proportional to the number of trials 
comparing this intervention to any other in the network. The lines connecting each pair of 
interventions represent a direct comparison and are drawn proportional to the number of 
trials making each direct comparison. 
 
 





Figure 5. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL by mode 





Figure 6. Cumulative rankograms comparing each of the uterotonic drugs for prevention of 
PPH ≥ 1000 mL by mode of birth (vaginal birth). Ranking indicates the cumulative 
probability of being the best drug, the second best, the third best, etc. The x axis shows the 
relative ranking and the y-axis the cumulative probability of each ranking. We estimate the 
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the 






Figure 7. Network diagram for prevention of PPH ≥ 500 mL by mode of birth (caesarean 
section). The nodes represent an intervention and their size is proportional to the number 
of trials comparing this intervention to any other in the network. The lines connecting each 
pair of interventions represent a direct comparison and are drawn proportional to the 






Figure 8. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL by mode 




Figure 9. Cumulative rankograms comparing each of the uterotonic drugs for prevention of 
PPH ≥ 500 mL by mode of birth (caesarean section). Ranking indicates the cumulative 
probability of being the best drug, the second best, the third best, etc. The x axis shows the 
relative ranking and the y-axis the cumulative probability of each ranking. We estimate the 
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the 








Figure 10. Network diagram for prevention of PPH ≥ 1000 mL by mode of birth (caesarean 
section). The nodes represent an intervention and their size is proportional to the number 
of trials comparing this intervention to any other in the network. The lines connecting each 
pair of interventions represent a direct comparison and are drawn proportional to the 






Figure 11. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL by mode 




Figure 12. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL by mode of birth (caesarean section). Ranking indicates the cumulative 
probability of being the best drug, the second best, the third best, etc. The x axis shows the 
relative ranking and the y-axis the cumulative probability of each ranking. We estimate the 
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the 






Figure 13. Network diagram for prevention of PPH ≥ 500 mL by prior risk for postpartum 
haemorrhage (low risk). The nodes represent an intervention and their size is proportional 
to the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 







Figure 14. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL by prior 





Figure 15. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL by prior risk for postpartum haemorrhage (low risk). Ranking indicates the 
cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 







Figure 16. Network diagram for prevention of PPH ≥ 1000 mL by prior risk for postpartum 
haemorrhage (low risk). The nodes represent an intervention and their size is proportional 
to the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 







Figure 17. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL by prior 






Figure 18. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL by prior risk for postpartum haemorrhage (low risk). Ranking indicates 
the cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 








Figure 19. Network diagram for prevention of PPH ≥ 500 mL by prior risk for postpartum 
haemorrhage (high risk). The nodes represent an intervention and their size is proportional 
to the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 






Figure 20. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL by prior 





Figure 21. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL by prior risk for postpartum haemorrhage (high risk). Ranking indicates 
the cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 







Figure 22. Network diagram for prevention of PPH ≥ 1000 mL by prior risk for postpartum 
haemorrhage (high risk). The nodes represent an intervention and their size is proportional 
to the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 





Figure 23. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL by prior 





Figure 24. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL by prior risk for postpartum haemorrhage (high risk). Ranking indicates 
the cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 






Figure 25. Network diagram for prevention of PPH ≥ 500 mL by healthcare setting (hospital 
setting). The nodes represent an intervention and their size is proportional to the number of 
trials comparing this intervention to any other in the network. The lines connecting each 
pair of interventions represent a direct comparison and are drawn proportional to the 







Figure 26. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL by 




Figure 27. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL by healthcare setting (hospital setting). Ranking indicates the cumulative 
probability of being the best drug, the second best, the third best, etc. The x axis shows the 
relative ranking and the y-axis the cumulative probability of each ranking. We estimate the 
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the 







Figure 28. Network diagram for prevention of PPH ≥ 1000 mL by healthcare setting (hospital 
setting). The nodes represent an intervention and their size is proportional to the number of 
trials comparing this intervention to any other in the network. The lines connecting each 
pair of interventions represent a direct comparison and are drawn proportional to the 







Figure 29. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL by 




Figure 30. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL by healthcare setting (hospital setting). Ranking indicates the cumulative 
probability of being the best drug, the second best, the third best, etc. The x axis shows the 
relative ranking and the y-axis the cumulative probability of each ranking. We estimate the 
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the 








Figure 31. Network diagram for prevention of PPH ≥ 500 mL by healthcare setting 
(community setting). The nodes represent an intervention and their size is proportional to 
the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 







Figure 32. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL by 





Figure 33. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL by healthcare setting (community setting). Ranking indicates the 
cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 







Figure 34. Network diagram for prevention of PPH ≥ 1000 mL by healthcare setting 
(community setting). The nodes represent an intervention and their size is proportional to 
the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 







Figure 35. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL by 





Figure 36. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL by healthcare setting (community setting). Ranking indicates the 
cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 






Figure 37. Network diagram for prevention of PPH ≥ 500 mL restricted to misoprostol 
studies that use a low dose (less or equal to 500 mcg). The nodes represent an intervention 
and their size is proportional to the number of trials comparing this intervention to any 
other in the network. The lines connecting each pair of interventions represent a direct 








Figure 38. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL restricted 
to misoprostol studies that use a low dose (less or equal to 500 mcg). 
 
 
Figure 39. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL restricted to misoprostol studies that use a low dose (less or equal to 500 
mcg). Ranking indicates the cumulative probability of being the best drug, the second best, 
the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 







Figure 40. Network diagram for prevention of PPH ≥ 1000 mL restricted to misoprostol 
studies that use a low dose (less or equal to 500 mcg).The nodes represent an intervention 
and their size is proportional to the number of trials comparing this intervention to any 
other in the network. The lines connecting each pair of interventions represent a direct 






Figure 41. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL restricted 
to misoprostol studies that use a low dose (less or equal to 500 mcg). Figure 66. Figure 
 
 
Figure 42. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL restricted to misoprostol studies that use a low dose (less or equal to 
500 mcg). Ranking indicates the cumulative probability of being the best drug, the second 
best, the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 






Figure 43. Network diagram for prevention of PPH ≥ 500 mL restricted to misoprostol 
studies that use a high dose (600 mcg or more). The nodes represent an intervention and 
their size is proportional to the number of trials comparing this intervention to any other in 
the network. The lines connecting each pair of interventions represent a direct comparison 






Figure 44. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 restricted to 
misoprostol studies that use a high dose (600 mcg or more). 
 
 
Figure 45. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL restricted to misoprostol studies that use a high dose (600 mcg or more). 
Ranking indicates the cumulative probability of being the best drug, the second best, the 
third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 






Figure 46. Network diagram for prevention of PPH ≥ 1000 mL restricted to misoprostol 
studies that use a high dose (600 mcg or more). The nodes represent an intervention and 
their size is proportional to the number of trials comparing this intervention to any other in 
the network. The lines connecting each pair of interventions represent a direct comparison 





Figure 47. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL restricted 
to misoprostol studies that use a high dose (600 mcg or more). 
 
 
Figure 48. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL restricted to misoprostol studies that use a high dose (600 mcg or more). 
Ranking indicates the cumulative probability of being the best drug, the second best, the 
third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 






Figure 49. Network diagram for prevention of PPH ≥ 500 mL restricted to oxytocin studies 
that used an intramuscular or intravenous bolus of any dose. The nodes represent an 
intervention and their size is proportional to the number of trials comparing this 
intervention to any other in the network. The lines connecting each pair of interventions 
represent a direct comparison and are drawn proportional to the number of trials making 





Figure 50. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 restricted to 
oxytocin studies that used an intramuscular or intravenous bolus of any dose. 
 
 
Figure 51. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 restricted to oxytocin studies that used an intramuscular or intravenous bolus 
of any dose. Ranking indicates the cumulative probability of being the best drug, the 
second best, the third best, etc. The x axis shows the relative ranking and the y-axis the 
cumulative probability of each ranking. We estimate the SUrface underneath this 
Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all 






Figure 52. Network diagram for prevention of PPH ≥ 1000 mL restricted to oxytocin studies 
that used an intramuscular or intravenous bolus of any dose. The nodes represent an 
intervention and their size is proportional to the number of trials comparing this 
intervention to any other in the network. The lines connecting each pair of interventions 
represent a direct comparison and are drawn proportional to the number of trials making 






Figure 53. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 restricted to 





Figure 54. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 restricted to oxytocin studies that used an intramuscular or intravenous 
bolus of any dose. Ranking indicates the cumulative probability of being the best drug, the 
second best, the third best, etc. The x axis shows the relative ranking and the y-axis the 
cumulative probability of each ranking. We estimate the SUrface underneath this 
Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all 






Figure 55. Network diagram for prevention of PPH ≥ 500 mL restricted to oxytocin studies 
that used an intravenous bolus plus an infusion of any dose. The nodes represent an 
intervention and their size is proportional to the number of trials comparing this 
intervention to any other in the network. The lines connecting each pair of interventions 
represent a direct comparison and are drawn proportional to the number of trials making 





Figure 56. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 restricted to 





Figure 57. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 restricted to oxytocin studies that used an intravenous bolus plus an infusion 
of any dose. Ranking indicates the cumulative probability of being the best drug, the 
second best, the third best, etc. The x axis shows the relative ranking and the y-axis the 
cumulative probability of each ranking. We estimate the SUrface underneath this 
Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all 






Figure 58. Network diagram for prevention of PPH ≥ 1000 mL restricted to oxytocin studies 
that used an intravenous bolus plus an infusion of any dose. The nodes represent an 
intervention and their size is proportional to the number of trials comparing this 
intervention to any other in the network. The lines connecting each pair of interventions 
represent a direct comparison and are drawn proportional to the number of trials making 





Figure 59. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 restricted to 




Figure 60. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 restricted to oxytocin studies that used an intravenous bolus plus an 
infusion of any dose. Ranking indicates the cumulative probability of being the best drug, 
the second best, the third best, etc. The x axis shows the relative ranking and the y-axis the 
cumulative probability of each ranking. We estimate the SUrface underneath this 
Cumulative RAnking line (SUCRA); the larger the SUCRA the higher its rank among all 






Figure 61. Network diagram for prevention of PPH ≥ 500 mL restricted to oxytocin studies 
that used an intravenous infusion only of any dose. The nodes represent an intervention 
and their size is proportional to the number of trials comparing this intervention to any 
other in the network. The lines connecting each pair of interventions represent a direct 







Figure 62. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 restricted to 
oxytocin studies that used an intravenous infusion only of any dose. 
 
 
Figure 63. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 restricted to oxytocin studies that used an intravenous infusion only of any 
dose. Ranking indicates the cumulative probability of being the best drug, the second best, 
the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 







Figure 64. Network diagram for prevention of PPH ≥ 1000 mL restricted to oxytocin studies 
that used an intravenous infusion only of any dose. The nodes represent an intervention 
and their size is proportional to the number of trials comparing this intervention to any 
other in the network. The lines connecting each pair of interventions represent a direct 






Figure 65. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 restricted to 




Figure 66. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 restricted to oxytocin studies that used an intravenous infusion only of any 
dose. Ranking indicates the cumulative probability of being the best drug, the second best, 
the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 











Figure 67. Network diagram for prevention of PPH ≥ 500 mL by quality of studies (high 
quality trials). The nodes represent an intervention and their size is proportional to the 
number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 






Figure 68. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL by quality 




Figure 69. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL by quality of studies (high quality trials). Ranking indicates the cumulative 
probability of being the best drug, the second best, the third best, etc. The x axis shows the 
relative ranking and the y-axis the cumulative probability of each ranking. We estimate the 
SUrface underneath this Cumulative RAnking line (SUCRA); the larger the SUCRA the 







Figure 70. Network diagram for prevention of PPH ≥ 1000 mL by quality of studies (high 
quality trials). The nodes represent an intervention and their size is proportional to the 
number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 






Figure 71. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL by 





Figure 72. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL by quality of studies (high quality trials). Ranking indicates the 
cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 






Figure 73. Network diagram for prevention of PPH ≥ 500 mL restricted to studies with 
funding source at low risk of bias (public or no funding). The nodes represent an 
intervention and their size is proportional to the number of trials comparing this 
intervention to any other in the network. The lines connecting each pair of interventions 
represent a direct comparison and are drawn proportional to the number of trials making 






Figure 74. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL restricted 





Figure 75. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL restricted to studies with funding source at low risk of bias (public or no 
funding). Ranking indicates the cumulative probability of being the best drug, the second 
best, the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 








Figure 76. Network diagram for prevention of PPH ≥ 1000 mL restricted to studies with 
funding source at low risk of bias (public or no funding). The nodes represent an 
intervention and their size is proportional to the number of trials comparing this 
intervention to any other in the network. The lines connecting each pair of interventions 
represent a direct comparison and are drawn proportional to the number of trials making 










Figure 77. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL restricted 





Figure 78. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL restricted to studies with funding source at low risk of bias (public or no 
funding). Ranking indicates the cumulative probability of being the best drug, the second 
best, the third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 







Figure 79. Network diagram for prevention of PPH ≥ 500 mL restricted to studies with an 
objective method of measuring blood loss. The nodes represent an intervention and their 
size is proportional to the number of trials comparing this intervention to any other in the 
network. The lines connecting each pair of interventions represent a direct comparison and 






Figure 80. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL restricted 






Figure 81. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL restricted to studies with an objective method of measuring blood loss. 
Ranking indicates the cumulative probability of being the best drug, the second best, the 
third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 






Figure 82. Network diagram for prevention of PPH ≥ 1000 mL restricted to studies with an 
objective method of measuring blood loss. The nodes represent an intervention and their 
size is proportional to the number of trials comparing this intervention to any other in the 
network. The lines connecting each pair of interventions represent a direct comparison and 






Figure 83. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL restricted 




Figure 84. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL restricted to studies with an objective method of measuring blood loss. 
Ranking indicates the cumulative probability of being the best drug, the second best, the 
third best, etc. The x axis shows the relative ranking and the y-axis the cumulative 
probability of each ranking. We estimate the SUrface underneath this Cumulative RAnking 






Figure 85. Network diagram for prevention of PPH ≥ 500 mL restricted to large studies        
(> 400 participants). The nodes represent an intervention and their size is proportional to 
the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 






Figure 86. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 500 mL restricted 





Figure 87. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 500 mL restricted to large studies (> 400 participants). Ranking indicates the 
cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 










Figure 88. Network diagram for prevention of PPH ≥ 1000 mL restricted to large studies      
(> 400 participants). The nodes represent an intervention and their size is proportional to 
the number of trials comparing this intervention to any other in the network. The lines 
connecting each pair of interventions represent a direct comparison and are drawn 




Figure 89. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analysis for prevention of PPH ≥ 1000 mL restricted 




Figure 90. Cumulative rankograms comparing each of the uterotonic drugs for prevention 
of PPH ≥ 1000 mL restricted to large studies (> 400 participants). Ranking indicates the 
cumulative probability of being the best drug, the second best, the third best, etc. The x 
axis shows the relative ranking and the y-axis the cumulative probability of each ranking. 
We estimate the SUrface underneath this Cumulative RAnking line (SUCRA); the larger the 






Figure 91. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 





Figure 92. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 





Figure 93. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 





Figure 94. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analyses for prevention of severe maternal 




Figure 95. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 





Figure 96. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 





Figure 97. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 





Figure 98. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 
network (combining direct and indirect) analyses for change in haemoglobin 




Figure 99. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 






Figure 100. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 




Figure 101. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 




Figure 102. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 




Figure 103. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 




Figure 104. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 




Figure 105. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 




Figure 106. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 




Figure 107. Forest plot with relative risk ratios and 95% CIs from pairwise, indirect and 










Additional data retrieved from Adanikin A, Orji E, Adanikin P, Olaniyan 
O. Comparative study of rectal misoprostol to oxytocin in preventing 
postpartum haemorrhage post caesarean section. International 
Journal of Gynecology and Obstetrics 119S3 (2012) S825: 
 
Objectives: In patients with risk factors for primary postpartum 
haemorrhage, it is generally considered good practice to administer 
an adjunctive uterotonic agent after the active management of the 
third stage of labour. Oxytocics that have been used in this adjunctive 
context include oxytocin infusion or rectal misoprostol as practised in 
our centre. Although this practise is popular in our environment, 
objective comparative assessment of these prophylactic measures is 
lacking. This study thus set out to compare the efficacy of both 
measures, the result of which may engender a change in the current 
practice in our centre and elsewhere or indeed strengthen it. 
Materials: Oxytocin, Rectal misoprostol. Placebo (Lactose tablet; 
Normal saline). Methods: In this comparative study, 218 parturients 
who delivered by caesarean section received 5 IU of intravenous 
oxytocin after cord clamping and were further randomized to receive 
either 600mcg rectal misoprostol and a placebo infusion intravenously 
or placebo rectally and an oxytocin infusion. 4 hours post-operative 
blood loss was estimated by application of pads of known weight. 
Results: The mean immediate 4 hours post-operative blood loss was 
not significantly different between the rectal misoprostol and oxytocin 
infusion group (106.65±30.64 ml versus 109.02±27.55 ml; p=0.553) 
and the change between the pre-operative and postoperative 
hematocrit was similar. No patient developed primary postpartum 
haemorrhage in the study. There was no statistically significant 
difference in the incidence of pyrexia and shivering. Conclusions: 
Post-caesarean section rectal misoprostol has comparative efficacy to 
oxytocin infusion in preventing postpartum haemorrhage after 
caesarean section. Misoprostol which can be stored at high 
temperatures and has a shelf life of several years should be favoured 
as ideal adjunctive uterotonic in developing countries with a tropical 
climate and limited refrigeration capabilities that is needed to maintain 
the potency of oxytocin. 
Al-Sawaf 2013 
Response to email queries: 
 
PPH > 500 ml No. Events Total No. Women 
Control 8     39 
Misoprostol 3     28 
Oxytocin 2     37 
 
PPH > 1000 ml No. Events Total No. Women 
Control 6     39 
Misoprostol 2     28 




Change in Hb after Delivery (g/dl)   Mean Hb Change SD    Total No. Women 
Control                1.3 0.6          39 
Misoprostol                1.3 0.9          28 
Oxytocin                1.2 0.9          37 
Amin 2014 
Response to email queries: 
 
Thanks for including my study in urban met analysis. The answers to 
u r questions are . 
1.all pt included in the study were admitted through emergency and 
ops. After complet history and examination pt with history of privious c 
. section. ,traumatic ppq. ,bleeding disorders. ,history of prolonged 
difficult labour, placenta previa, placetal abruption, history of pph. 
,multiple gestation and women having BMi more than 30 were 
excluded. However all other pt with full term pregnancy and who came 
to labour room in spontaneous onset of labour resulting in 
spontaneous vaginal delivery without episiotomy were included in the 
study.  
2.as I expand before that high risk pt were not included in study so no 
death and major morbidity been noted. 
Askar 2011 
Response to email queries: 
 
Hypertension 3rd Stage 30-60 mins  3rd Stage 60-120 mins Total of Patients 
Intervention (Carbetocin)       0                0      0 
Control (Syntometrine)           7                7      7 (these are 
the same patients) 
Attilakos 2010 
Response to email queries: 
 
Carbetocin Oxytocin 
1 Nausea 2Nausea 
2 Nausea+Flushed 3 Vomiting  
1 Nausea+Headache 1 Vomiting+Trigeminy 
1 Nausea+Abdominal pain 1 Nausea+Headache 
2 Nausea+Vomiting 2 Nausea+Vomiting 
1 Nausea+Vomiting+Sweating 1 Nausea+Vomiting+SOB 
1 Nausea+Vomiting+Tremors 1 Nausea+Flushed+Tremors 
1 Nausea+Vomiting+Flushed+Hypotension 1 
Nausea+Vomiting+Flushed+Tremors 
1 Tightness throat 2 Dizziness 
2 Dizziness 1 Dizziness+Flushed+Sweating 
1 Flushed 2 Hypotension 
2 Hypotension 2 Tremors 
1 Hypotension+SOB 1 SOB 
1 ST Depression 1 Blurred vision 
1 Tachycardia 1 Metallic taste 
1 Tremors+Tachycardia 1 Pain in arm  
1 Metallic taste+SOB+Wheezing 1 Abdominal pain+SOB 
1 Metallic taste+POF 1 Backache 
1 Headache 1 Headache 




SOB = Shortness OF Breath 
POF = Pressure Over Forehead 
Atukunda 2014 
Attachment to response to email queries: 
 
Vomiting (generally) Events Total 
Misoprostol  35(6.1)  569 
Oxytocin  19(3.3)  570 
 
Vomiting (severe) Events Total 
Misoprostol  8(1.4)  569 
Oxytocin  3(0.5)  570 
  
Morbidity (extensive vaginal repair) Events Total 
Misoprostol                       11(1.9)       570 




Response to email queries: 
 
We did not document the routine drugs used in the active 
management of labour in each case. At two sites in South Africa (East 
London and Dora Nginza, Port Elizabeth), and in Uganda the routine 
was oxytocin 10u IM. At the third site in SA (Rob Ferreira) oxytocin 5u 
IM was used in 60/155 and oxytocin-ergometrine (5u/0.5mg) was 
used in 85/155. In Nigeria either oxytocin or ergometrine was used, 
but we don’t have the details. As this was a randomized trial, we 
expected the routine management to be evenly distributed between 
the randomized groups.  
Begley 1990 
Response to email queries: 
 
Random number tables were used from the statistical text-book by 
Fleiss (1981). The first number was selected from the table by a 
disinterested observer and the numbers were then allocated in blocks 
of 100, following in sequence.  
 
Duration 3rd Stage Mins 0-20 21-40 41-60 61-80 81-100 102-120  >120 Mean        
SD/CI Total  
Intervention (Active)           674    11    4    0     2      8            6   11.26  
19.62  705 
Control (Physiological)        670    41    7    1     4      1            0   11.56  
8.41    724 
 
Change in Hb (g/dl) Mean Change  SD/CI Total Number of Patients 
Intervention (Active) +0.91            1.19                                618 
Control (Physiologocal) +0.47             1.27                                645 
Bellad 2012 
Response to email queries: 
 
Four women in the misoprostol group and none in the oxytocin group 
experienced fever (defined as ?38º C); this was entered onto the form 
as a dichotomous variable and we have no information regarding the 
actual temperature (or whether any woman experienced a 
temperature of ?40º C). One woman in the oxytocin group had 
retained placenta and a blood transfusion; this was the only case of 
 
 
transfusion and required ICU admission for monitoring. There were no 
other complications (e.g., organ failure) and no maternal deaths. 
 
58/329 women receiving oxytocin (17.6%) had second stage of labor 
>=30 minutes.  
53/323 women receiving sublingual misoprostol (16.4%) had second 
stage of labor >=30 minutes.  
1 woman receiving oxytocin and no women receiving sublingual 
misoprostol had a third stage of labor >=30 minutes. 
Bhullar 2004 
Response to email queries: 
 
I don’t have the raw data anymore, but I am certain we did not have 
any maternal deaths. 
Bugalho 2001 Additional data extracted from published Cochrane review(s)  
Chaudhuri 2012 Additional data extracted from published Cochrane review(s) 
Chhabra 2008 
Response to email queries: 
 
You know this was low dose study in low risk cases for prophylaxis. 
So the answers are: 
 
The number of women (n/N) in each study group (if any) who needed 
major surgery - nil 
The number of women (n/N) in each study group (if any) who needed 
ICU admission - nil 
The number of women (n/N) in each study group (if any) who had 
hyperpyrexia (T>40) - nil 
The number of women (n/N) in each study group (if any) who had vital 
organ failure - nil 
The number of women (n/N) in each study group (if any) who had an 
estimated blood loss >1000mls - nil 
The number of women (n/N) in each study group (if any) who died - nil 
Dansereau 1999 
Response to email queries: 
 
Thank you again for your interest. What I meant to clarify previously is 
that the paper should have stated that “two patients in each group had 
a [severe] postpartum hemorrhage [requiring blood transfusion]”. 
Because of the difficulty in assessing estimated blood loss, we had 
decided -before the beginning of the study- to not use that variable but 
rather, to use the judgment of the surgeon (blinded to the study drug), 
as to whether the patient needed additional oxytocic (required in all 
cases of PPH). Clearly more than two patients per group had a PPH 
greater than 500 or even 1000 ml. The exact number is not available 
though as we decided not to use that outcome of PPH in our study. 
El Behery 2015 
Response to email queries: 
 
PPH > 500 ml Events  
Carbetocin           6 




Major morbidity or death 
Carbetocin            0   
Oxytocin  3 
 
I confirm that we actually excluded cases listed below from our study: 
congenital fetal anomalies, placenta previa, diabetes, hypertension, 
preeclampsia, cardiac disorders, general anaesthesia 
El Tahan 2012 
Response to email queries: 
 
I will address below your queries as follows:  
 
Any maternal deaths: no  
Maternal ICU admissions: no 
Hysterectomies: no 
Maternal fever >40C: there were 16/179 cases developed pyrexia <40 
C in misoprostol group; none exceeded 40C.  
Blood loss of >1000mls: yes some cases in the placebo group had a 
total perioperative blood loss >1000 ml 
Enakpene 2007 
Response to email queries: 
 
There was no death recorded in either group 
None of the study participants required additional surgery such as 
hysterectomy or arterial ligation to treat massive postpartum 
hemorrhage. 
There was only one ICU admission in the misoprostol group for non-
hemorrhage related condition but due to postpartum eclampsia. 
No participants in each study group developed hyperpyrexia of 
temperature > 40oC 
No participants developed major organ failure 
Three participants from the oral misoprostol group had massive 
postpartum hemorrhage greater than 1000ml while only one 
participants in the methylergometrine group developed massive 
postpartum hemorrhage. However, all the four patients who 
developed massive hemorrhage responded very well with additional 
oxytocics and did not require surgical interventions. 
Fawole 2011 
There were no women who experienced hyper-pyrexia (T  40) or vital  
organ failure, or who needed ICU admission, in either the intervention 
or control group. 
Fenix 2012 
Additional data retrieved from an unpublished text entitled “Double-
blind randomized controlled trial comparing the effect of carbetocin 
with oxytocin for the prevention of postpartum hemorrhage among 




The study was conducted over a 4-month period (from May 2011 to 
August 2011). There were a total of 272 deliveries in our hospital 
during the study period, of which, 111 delivered vaginally. 75 women 
 
 
were finally recruited into the study. Nine women in the carbetocin 
group and six women in the oxytocin group failed to have a paired 
hemoglobin test to measure the change in hemoglobin 24 hours after 
delivery because they refused further blood extraction. These 15 
women were excluded, and we therefore had 30 women each in the 
carbetocin and oxytocin arm in the analysis that was randomly 
assigned to receive either of the two different interventions. 
 
There was no significant difference between the two groups in their 
demographic characteristics (Table 1). Most of the participants were 
college degree holders with an average age of 30 years. The average 
age of gestation was 38 weeks for the carbetocin group while almost 
39 weeks in the oxytocin group. It was also observed that about two 
thirds were multigravid women for both groups.  
 
The average hemoglobin count 24 hours after delivery of the 
participants for the oxytocin group (-1.1) seems to have a greater drop 
than those in the carbetocin group (-0.6) (Table 2).  
 
Participants in the carbetocin group exhibited a relatively lower 
average estimated blood loss than those in the oxytocin group (296 cc 
and 493 cc respectively). There was no case of postpartum 
hemorrhage between the two groups. The distribution of exposure to 
additional agents revealed that 9 out of 10 patients in the oxytocin 
group needed additional uterotonic agents. In contrast, 90% of the 
participants in the carbetocin group did not need any additional agent 
after drug administration. In addition, it was noted that almost all of the 
patients in the oxytocin group needed a uterine massage compared to 
a negligible number of those in the carbetocin group. Meanwhile, none 
of the patients needed blood transfusion. (Table 3)  
 
Carbetocin immediately (1min) took effect to the patients in the 
carbetocin group while those patients in the oxytocin group waited for 
some time (30 min or more) for oxytocin to take effect (Table 3).  
 
Adverse effects are presented in Table 4. The incidences of headache 
and hypogastric pain were similar in between groups. There were no 
nausea, vomiting, facial flushing or pain in the injection site noted.  
 
20% percent or 6 out of 30 women in the carbetocin group had 
tachycardia (defined as maternal pulse ‡100) within 60 minutes 
postdelivery and were significantly higher than the 10% (3 out of 30) 
recorded in the oxytocin group however, the difference was 
statistically insignificant. The mean blood pressure values at different 
intervals after delivery of each group are also shown in Table 4 though 
no statistical difference was observed between the two interventions. 
 
To determine if there is a significant difference between the two drugs, 
we will need to perform independent sample T-Test. Prior to 
performing the test, we need to satisfy its assumptions which is as 
follows: (a) normality of the data, (b) homogeneity / constancy of 




Based on the results in Table 5, we can conclude that there’s a 
significant difference between the Carbetocin and Oxytocin since the 
p-values for the Estimated Mean Blood Loss and Mean difference of 
the Hemoglobin count are approximately zero (< LOS = 0.05). 
 
Looking at the mean difference of the hemoglobin count, having a 
value of 0.57 implies that carbetocin garnered a significantly lower 
change in the hemoglobin count after 24 hours. 
 
The mean difference of the estimated blood loss, with value of -
197.33, denotes statistically lower blood loss for patients exposed to 
carbetocin than those who were exposed to oxytocin. 
 
Table 1 Baseline Characteristics of Patients 
 
 


























Appendix A Q-Q plot of difference of preoperative hemoglobin count 








Response to email queries: 
 
Regarding your query on the incongruity on 30 parturients receiving 
oxytocin with mean blood loss of 493ml but 0 cases more than 500ml, 
it was because the estimated blood loss during delivery was 
measured only through eyeballing of the gauzes used. And in the 
estimation, we did not include the bleeding coming from repair of the 
laceration. That is why one of our recommendations for future studies 
is to measure the actual blood loss using a more accurate device of 
measurement. And also, since the estimation of blood loss is often 
inaccurate during delivery, it was agreed that a fall in hemoglobin be 
used as a primary outcome assessing the efficacy of the uterotonic 
agents in reducing postpartum hemorrhage. 
Gavilanes 2015 
Response to email queries: 
 
PPH 500- 1000 ml Events Total 
Misoprostol             33             50 
Oxytocin             26                 50  
  
PPH > 1000 ml Events Total 
Misoprostol            12          50  
Oxytocin            13         50 
 
None of our patients had major morbidity. There were no deaths 
neither. 
Gulmezoglu 2001 Additional data extracted from published Cochrane review(s) 
Hofmeyr 1998 
Response to email queries: 
 
            Misoprostol (n=36)   Placebo (n=37) RR                95% CI         p 
> 500ml 8 (22%)         15 (41%) 0.55     0.27-1.13 0.15 
> 1000ml 2 (5.6%) 5 (14%) 0.41     0.09-1.98 0.23 
Add.oxytocic   2 (5.6%) 7 (19%) 0.29     0.07-1.32 0.08 
Hofmeyr 2011 
Response to email queries: 
I've checked the original data: all 9 pyrexias were between 39 and 
39.9, none 40 or more. 
 
The only severe morbidity we recorded were the 9 laparotomies, of 
whom one had hysterectomy. 
 
There was no overlap of data. The Nigeria site in Hofmeyr 2011 was 
University College Hospital, Ibadan. Fawole 2011 included two other 
hospitals in Ibadan and other Nigerian sites. Univ college hospital 
occurs in the title as that is bukola's base, but was not a site. 
 
Additional data also retrieved from Hofmeyr GJ, Gülmezoglu AM, 
Novikova N, Linder V, FerreiraS, Piaggio G. Misoprostol to prevent 
and treat postpartum haemorrhage: a systematic review and meta-
analysis of maternal deaths and dose-related effects. Bulletin of the 




Additional data also retrieved from Hofmeyr GJ, FerreiraS, Nikodem 
VC, Mangesi L, Singata M, Jafta Z, Maholwana B, Mlokoti Z, 
Walraven G, Gülmezoglu AM. Misoprostol for treating postpartum 
haemorrhage: a randomized controlled trial [ISRCTN72263357]. BMC 
Pregnancy and Childbirth 2004, 4:167. 
Jerbi 2007 
Response to email queries: 
 
No blood loss more than 1000ml in any group. 
No transfusion or maternel death in the 2 groups. 
Lapaire 2006 
Response to email queries: 
 
“Calculated” blood loss: 
 Misoprostol (n=24)  Oxytocin (n=19) 
> 500 ml 18            15 
>1000 ml 13            11 
 
“Estimated” blood loss: 
 Misoprostol (n=28)  Oxytocin (n=28) 
> 500 ml 18            10 
>1000 ml 1            14 
Musa 2015 
Response to email queries: 
 
There was on postpartum blood loss > 1000ml in both group. Range 
of blood loss was 20-790ml in misoprostol group and 40-790 in 
oxytocin group. There was no maternal death recorded though 
participants were followed up only in the early puerperium. There was 
no major morbidity. The only morbidity recorded was retained 
placenta that warranted manual removal of placenta. The two cases 
occur in oxytocin group and none in misoprostol group. 
Nasr 2009 
Response to email queries: 
 
Regarding your queries, I write to confirm that NO women in either 
group needed major surgery or ICU admission, nor did any have 




Response to email queries: 
 
The method of randomisation was made by our Statistical department, 
and I believe it was a computer-generated sequence. 
Owonikoko 2011 
Response to email queries: 
 
PPH > 500 ml             Events 
Sublingual Misoprostol 34 
Intravenous Oxytocin  27 
  
PPH > 1000 ml              Events 
Sublingual Misoprostol  4  





Blood loss (ml)     Mean        SD/CI         Total 
Sublingual Misoprostol 667.12mls 213.38 50  
Intravenous Oxytocin 649.90mls 251.15 50 
  
Change in Hb (%) Mean SD/CI Total  
Sublingual Misoprostol 4.5 3.3            50  
Intravenous Oxytocin 4.3  2.97 50 
Parsons 2007 




 Stage >30 Mins  Mean (Mins) SD                  CI              Total  
Intervention         3  6.95  6.11(SD)  6.13-7.76 (CI)   218 
Control         2  6.18  4.62(SD)  5.57-6.79(CI)   222 
Rosseland 2013 
Response to email queries: 
 
The data on estimated blood loss is the visually estimated blood loss 
in the OR. As you can read in the article we believe these data are of 
limited value and have based our analyses of blood loss on change in 
Hb instead. A strict perioperative IV fluid protocol was followed, of 
course. 
 
PPH > 500 ml Events  Total 
Oxytocin 4  26 
Carbetocin  6  25 
Placebo  8  25 
  
PPH > 1000 ml Events  Total 
Oxytocin 0  26 
Carbetocin 0  25 
Placebo  0  25 
 
Change in Hb (g/dl) Mean SD/CI Total  
Oxytocin -0.82 0.67 26  
Carbetocin -0.50 0.82 25 
Placebo  -0.84 0.53 25 
  
Change in Hb (%) Mean SD/CI Total  
Oxytocin 27.9 14.1 26  
Carbetocin 25.6 13.6 25 
Placebo  15.7 16.5 25 
Sadiq 2011 
Response to email queries: 
 
For fever, there wasn't any patient lost to follow up because each 
round of study lasted only 24 hours, and throughout this period, the 
patients were hospitalized (admitted). 
 
For fever, we have full data set, but some of the data were published 
elsewhere (an act that will probably sound strange to you). 
 
There wasn't death in the study (another fact that may probably sound 
 
 
strange, despite the global reports on maternal mortality in Nigeria). 
 
There were differences in baseline characteristics like age, parity, etc. 
however, we thought to have minimize the effects of these differences 
through randomization of treatment - even though what was done was 
not the literary meaning of the term 'randomization' since we did not 
initially consider a specific patient population. However, we suggested 
further studies (in my reports) whereby baseline characteristics are 
made uniform between the two groups. In case of baseline treatment 
with oxytocin; there is clear demarcation in that the Misoprostol group 
had no pretreatment with oxytocin. 
Samimi 2013 
Response to email queries: 
 
Because our aim of this study was prevention of PPH not treatment of 
PPH, therefore we had not mortality or morbidity in our study 
population, also we used of hemoglobin as indicator of blood loss 
instead of measurement of blood loss volume. 
Shrestha 2011 
Response to email queries: 
 
We did not find hyperpyrexia (T>40), vital organ failure, ICU 
admission, surgery, or who died, in either the intervention or control 
group of this study. 
Tewatia 2014 
Response to email queries: 
 
PPH > 500 ml: Events  
Misoprostol 0   
Oxytocin o  
  
PPH > 1000 ml: Events 
Misoprostol 0  
Oxytocin 0   
 
Death: Events 
Misoprostol 0  
Oxytocin 0   
 
Morbidity: Events 
Misoprostol fever 13, shivering 10,nausea 1, vomiting 1   
Oxytocin nausea 1, vomiting 1  
Ugwu 2014 
Response to email queries: 
 
PPH > 500ml Event Total 
Misoprostol  15 60 
Oxytocin 33 60 
  
PPH> 1000ml Event Total 
misoprostol 1 60 




Death Event Total 
Misoprostol 0 60 
Oxytocin 0 60 
  
Morbidity Events Total 
Misoprostol 0 60 
Oxytocin 0 60 
Walley 2000 
Response to email queries: 
 
3rd stage >30 mins Mean (mins) SD CI 
misoprostol                  6.15               3.76 5.62-6.69 
oxytocin                  7.30              13.08  5.40-9.19 
 
3rd stage >30 mins Events Total 
Misoprostol                     0       194 
Oxytocin                     2  185 
Whigham 2014 
Response to email queries: 
 
Carbetocin vs oxytocin in non-elective C/S   
   
PPH>500ml Events total 
Carbetocin 42 59 
Oxytocin 37 53 
 
PPH>1000ml Events Total 
Carbetocin 6 59 
Oxytocin 6 53 
 
Active labour at time of C/S   
   
PPH>500ml Events Total 
Carbetocin 22 30 
Oxytocin 19 28 
 
PPH>1000ml Events Total 
Carbetocin 4 30 
Oxytocin 3 28 
Zachariah 2006 
Response to email queries: 
 
We did not have any maternal deaths in any of the study groups. 
 
 
 
